FDA Approves Lilly's Cymbalta
The U.S. Food and Drug Administration has approved Cymbalta(R) (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company (NYSE: LLY) announced today.
Cymbalta, a balanced and potent reuptake inhibitor of serotonin and norepinephrine, has been studied in more than 6,000 adults with major depression worldwide. Its approval gives healthcare professionals and patients a long-awaited new option for treating the broad range of emotional and physical symptoms of depression. Today, only 25 35 percent of patients treated for depression in clinical studies experience relief from all of their disease symptoms.
Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for treating depression, anxiety disorder and pain associated with diabetic peripheral neuropathy or fibromyalgia. Other drugs in this class include milnacipran (Savella), venlafaxine (Effexor), and desvenlafaxine (Pristiq). Duloxetine affects neurotransmitters, the chemicals that nerves within the brain make and release in order to communicate with one another. Neurotransmitters either travel across the space between nerves and attach to receptors on the surface of nearby nerves or they attach to receptors on the surface of the nerves that produced them, to be taken up by the nerve and released again (a process referred to as re-uptake).
Cymbalta is an antidepressant in a group of drugs called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). Cymbalta affects chemicals in the brain that may become unbalanced and cause depression.
Cymbalta is used to treat major depressive disorder and general anxiety disorder. It is also used to treat a chronic pain disorder called fibromyalgia, and to treat pain caused by nerve damage in people with diabetes (diabetic neuropathy).
What is Cymbalta medication/Antidepressants?
Cymbalta, a brand name from Eli Lilly for a drug called duloxetine, is in a class of drugs known as dual uptake inhibitors. Cymbalta medically formulated as Duloxetine Hydrochloride is a new revolutionary antidepressent. What is interesting is that it is SNRI (serotonin and noradrenaline uptake inhibitor) in which previously only Effexor was the only FDA approved drug it that class. At this time very few effectiveness studies are available for cymbalta.
Uses and benefits of Cymbalta:
Cymbalta offers relief from both the emotional and physical symptoms that are associated with depression. Cymbalta is indicated for the treatment of major depressive disorder (approved 4 August, 2004), as well as for the management of diabetic peripheral neuropathic pain (DPNP - approved 7 September 2004). A new antidepressant called duloxetine improved symptoms of fibromyalgia -- a chronic and painful musculoskeletal disorder in women.